Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

Alfonse T. Masi · Arthritis & Rheumatism · 1980 · 4.9K citations

Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide

Frédéric Houssiau, Carlos Vasconcelos, David D’Cruz et al. · Arthritis & Rheumatism · 2002 · 1.1K citations · Full text

Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis

Barbara White, Wendy C. Moore, Fredrick M. Wigley et al. · Annals of Internal Medicine · 2000 · 384 citations

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

Charles D. Radis, Leslie E. Kahl, Gary L. Baker et al. · Arthritis & Rheumatism · 1995 · 313 citations

Cancer in systemic sclerosis

Mahmoud Abu‐Shakra, Francis Guillemin, Peter Lee · Arthritis & Rheumatism · 1993 · 215 citations